DarshanTalks Podcast

Send us Fan Mail

Episode Summary

When an AI model designs a novel therapeutic molecule or predicts an enzyme structure, who legally owns the resulting intellectual property? In this episode of Darshan Talks / KF Deep Dive, host Darshan Kulkarni turns the microphone over to Stu Angus (Founder of Scriptome.AI) for a reverse interview exploring the legal, regulatory, and philosophical chasms surrounding AI-generated pharma assets.

Together, they confront the core requirement of "human ingenuity" in patent law across the U.S. and Europe, examining why fully autonomous AI discoveries risk being legally unpatentable and open to generic exploitation. From patient consent scope in mega-tech partnerships (Eli Lilly, NVIDIA, Anthropic) to the limits of trade secrets, this episode provides a vital roadmap for biotech founders and life science executives navigating the AI revolution.

What You'll Learn in This Episode:

• The Human Inventorship Barrier: Why patent offices routinely reject AI as a sole inventor and how to establish "human ingenuity" in lab notebooks and prompts.
• Big Tech & Pharma Partnerships: Vetting patient consent when sharing trial data across multi-party platforms like Claude or NVIDIA.
• The In-Silico Valuation Trap: Why multi-billion-dollar AI licensing deals can collapse if underlying assets lack verified human inventorship.
• Patents vs. Trade Secrets: The limits of relying on trade secrets for AI-generated molecules under increasing FDA transparency rules.
• AI Personhood & Emergent Rights: A philosophical deep dive into whether autonomous AI systems could eventually claim legal rights over their own creations.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Episode Summary: Can a clinical trial site network legally enforce a standardized, templated employment agreement containing restrictive covenants against a Principal Investigator (PI) across state lines? In this episode of the KF Deep Dive, host Darshan Kulkarni breaks down why relying on "corporate uniformity" and copy-pasted employment templates is a ticking legal time bomb for scaling site networks.

Darshan explains how widely divergent state statutes governing healthcare non-competes—ranging from complete bans in states like Washington to strict statutory carve-outs in Texas—render standardized agreements completely unenforceable or even unlawful. He unpacks the downstream risks to Clinical Trial Agreements (CTAs), choice-of-law clauses, and sponsor relationships when a high-performing PI leaves and takes key protocols or study coordinators with them.

What You'll Learn in This Episode:

• The Template Trap: Why one master employment agreement with standard non-compete/non-solicit provisions fails across multiple state jurisdictions.
  
  
• State Law Fracture: How state-specific rules (e.g., Washington bans, Virginia severance conditions, Texas statutory buyouts) invalidate one-size-fits-all contracts.
  
  
• Judicial Modification Differences: Blue-pencil states vs. non-severability states, and why overly broad clauses can expose employers to statutory penalties.

• Impact on Clinical Trial Agreements: How PI turnover and contract disputes directly imperil study oversight, sponsor continuity, and trial pipelines.

• 4 Actionable Steps for Site Owners: How to conduct multi-state audits, transition from broad non-competes to hyper-tailored non-solicits, and leverage retention structures over trade restraints.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Episode Summary: "We are 100% HIPAA compliant." If this claim sits on your clinical trial site, digital health app, or pharma landing page, you may be quietly accumulating catastrophic compliance debt. In this episode of the KF Deep Dive, host Darshan Kulkarni sits down with technology and privacy attorney Brandi Bennett (Founder & Managing Partner of Bennett Tech Law) to tear down the dangerous myths surrounding health data privacy, web security badges, and commercial data contracts.

Together, they bypass generic HIPAA talking points to focus on the operational realities facing life sciences executives today. From the surge in state-level privacy audits targeting tracking pixels to the hidden liabilities of copy-pasting privacy policies or using generative AI to write legal notices, Brandi and Darshan reveal how unverified compliance claims directly expose companies to regulatory enforcement and deceptive trade practice lawsuits.

What You'll Learn in This Episode:

• The "Certification" Myth: Why there is no official government HIPAA certification or GDPR stamp—and how claiming "100% compliance" invites immediate regulatory audits.
• State-Level Enforcement Surges: How State Attorneys General inspect digital health stacks, wearables, and third-party adtech tracking scripts under state privacy laws.
• The AI Privacy Policy Trap: Why generating privacy notices via ChatGPT creates direct evidence of deceptive practices during regulatory investigations.
• Cyber Insurance Baselines: How a lack of documented, verified security controls guarantees failure during insurance underwriting and blocks institutional sponsor contracts.
• Control vs. Ownership: Why modern privacy negotiations should stop arguing over data "ownership" and focus on data control, access rights, and specific purpose limitations.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Episode Overview: In this episode of KLF Deep Dive, host Darshan Kulkarni sits down with Deborah Williams, Founder of Health Policy Insights, LLC, to explore over three decades of healthcare policy evolution. Deborah brings a wealth of experience as a policy researcher, former congressional staffer, and former lobbyist to break down the complexities surrounding the 340B Drug Pricing Program, hospital outpatient payments, and legislative mechanics on Capitol Hill.

Key Topics Covered:

• The Origins of 340B: How initial legislative intent, incomplete data, and early Medicaid rebate structures led to ongoing 30-year policy debates.
• Jurisdiction on Capitol Hill: How different Congressional committees—including Energy & Commerce, Finance, and HELP—shape healthcare and drug pricing legislation.
• Legislative "Styles": The structural differences between broad, intent-focused drafting versus hyper-detailed, line-by-line statutory writing.
• The Post-Chevron Landscape: What the end of Chevron deference means for hospital outpatient provisions and agency enforcement.
• Affordability vs. Funding: Addressing the core systemic issues facing safety-net hospitals and drug affordability in America today.

Connect with Deborah Williams: Reach out directly via Deborah Williams on LinkedIn for questions on 340B compliance and healthcare policy insights.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The wellness industry is undergoing a massive boom, but modern contrast therapy, thermal bathing, and sauna facilities are stepping directly into an unseen legal grid. In this episode of the Darshan Live podcast, host Darshan Kulkarni sits down with healthcare regulatory attorney Kate Woods and former public defender turned sauna master Mackenzie Boling to pull back the curtain on the regulatory boundaries of thermal wellness.

Together, they explore why saunas remain largely unregulated despite their intense physiological impact, how expanding bathhouses face mounting municipal water right battles alongside industrial tech data centers, and why proactive compliance—from pre-build site scans to immersive risk reviews—is essential for founders and operators today.

What You'll Learn in This Episode:

• Terminological Nuances: The operational and legal distinctions between standard saunas, contrast therapy, and broad thermal bathing.
• Inevitable Jurisdiction: Why unregulated modalities will soon draw regulatory oversight and how operators can prepare proactively.
• Pre-Build Compliance: Why conducting early site and plumbing scans prevents catastrophic, retroactive compliance costs.
• The Water Rights Crisis: How municipal water allocations, snowpack shortages, and local competition threaten expanding bathhouse footprints.
• Immersive Risk Audits: Aligning public marketing representations with client waivers and health disclosures to safeguard against liability.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

When podcast hosts and biohacking influencers promote "The Wolverine Stack"—coupling BPC-157 and TB-500 for rapid tissue and gut repair—it generates millions of dollars in consumer demand. But how does viral influencer marketing translate into real-world legal and regulatory risk? In this episode of Darshan Talks /KLF Deep Dive, host Darshan Kulkarni breaks down the myth versus the science behind BPC-157 (Body Protection Compound-157) and the legal pitfalls facing wellness clinics, compounding pharmacies, and life sciences brands.

Darshan examines the transition of BPC-157 from promising rodent studies to its initial placement in the FDA's Category 2 bulk compounding list—a regulatory dead zone for substances with significant safety concerns. He dissects the drama surrounding the Pharmacy Compounding Advisory Committee (PCAC) and its razor-thin 8-6 split vote recommending BPC-157 for Section 503A bulk compounding. Crucially, Darshan explains why an advisory committee vote is not an FDA approval and why selling unapproved, misbranded injectable peptides online creates massive civil and criminal liability.

Holt Law+ 2

What You'll Learn in This Episode:

• Rodent Science vs. Human Proof: Why early-stage animal data fails to establish human safety, proper dosing, or long-term efficacy.
• 
  RAPS
• Immunogenicity & Safety Unknowns: The real risks of injecting uncharacterized synthetic peptides, including severe injection site reactions and tissue proliferation.
• 
  RAPS
• Category 2 vs. 503A Compounding: How section 503A of the FD&C Act was leveraged by compounding pharmacies and why the FDA designated BPC-157 as a Category 2 bulk substance.
• 
  Holt Law
• The Tense PCAC 8-6 Split Vote: Inside the controversial advisory committee hearing, panel member composition, and FDA staff's continued opposition over lack of quality standards.
• 
  RAPS
• Advisory Vote vs. Legal Status: Why an advisory vote does not automatically make compounding legal and the immediate "failure to warn" and misbranding risks for wellness providers.
• 
  Bass, Berry & Sims PLC

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

What is happening inside the FDA, and how are regulatory shifts impacting pharmaceutical, medical device, and food companies? In this episode of the KLF Deep Dive, host Darshan Kulkarni sits down with veteran Food and Drug lawyer Alan Minsk (Partner and Chair of the Food & Drug Practice at Arnall Golden Gregory LLP) to discuss the evolving enforcement climate, agency turnover, and global supply chain challenges.

Together, they break down the structural impact of government efficiency initiatives (DOGE) on FDA staff morale and resources, the surge in direct-to-consumer (DTC) advertising enforcement, and shifting focus toward food safety, dietary supplements, and alternative treatments. Alan and Darshan also unpack offshore manufacturing scrutiny, virtual inspections, and how emerging trade dynamic policies like the BIOSECURE Act affect cross-border IP and pharmacovigilance.

What You'll Learn in This Episode:

• Agency Morale & Resources: How leadership turnover and budget cuts affect review times, reviewer retention, and day-to-day regulatory interactions.
• DTC & Promotional Enforcement: Why the FDA is leveraging AI and data tools to rapidly issue untitled and warning letters targeting prescription drug advertising.
• Manufacturing Scrutiny & Virtual Auditing: How FDA holds ex-US manufacturing plants accountable through email-based virtual inquiries and border holds.
• Reshoring vs. Offshore Risk: The decision matrix for large versus small pharma companies when considering US-based manufacturing footprint expansion.
• Cross-Border Dynamics & Biosecure Rules: Navigating pharmacovigilance data sharing and licensing agreements with overseas partners, particularly in China and Japan.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Thinking about launching a health tech startup, digital health app, or wearable device? Moving fast and breaking things might work in software, but in healthcare, breaking things means breaking people. In this episode of the KLF Deep Dive, host Darshan Kulkarni connects with Emily Hu Shapiro—a Silicon Valley native, chemical/biomedical engineer, former Google clinical research lead, powerlifter, and startup investor—to bust the myth of the solo "garage startup" in medical devices.

Emily breaks down why building a compliant medical device requires deep domain experts from day one in quality, regulatory, clinical, and manufacturing. From navigating strict FDA claims and avoiding the traps of "vibe coding" with AI to leveraging top accelerators like Y Combinator and knowing when to hire regulatory consultants over costly legal teams, this conversation is an essential guide for early-stage founders and health tech innovators.

What You'll Learn in This Episode:

• Big Tech vs. Garage Startups: Why getting big company experience first prevents fatal compliance and FDA submission mistakes.
• Intended Use & Regulatory Claims: How your product's marketing claims dictate your FDA classification and reimbursement pathway.
• The "Vibe Coding" Reality Check: The hidden regulatory and quality system risks of using AI-generated code for software as a medical device (SaMD).
• Smart Resource Allocation: How early-stage founders should prioritize regulatory, IP, and privacy guidance when funding is tight.
• Founder Red Flags: Why founder temperament, adaptability, and operational grit determine investor interest in digital health.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The wellness industry is undergoing a massive boom, but modern contrast therapy, thermal bathing, and sauna facilities are stepping directly into an unseen legal grid. In this episode of the KLF Deep Dive, host Darshan Kulkarni sits down with healthcare regulatory attorney Kate Woods and former public defender turned sauna master McKenzie Bowling to pull back the curtain on the regulatory boundaries of thermal wellness.

Together, they explore why saunas remain largely unregulated despite their intense physiological impact, how expanding bathhouses face mounting municipal water right battles alongside industrial tech data centers, and why proactive compliance—from pre-build site scans to immersive risk reviews—is essential for founders and operators today.

What You'll Learn in This Episode:

• Terminological Nuances: The operational and legal distinctions between standard saunas, contrast therapy, and broad thermal bathing.
• Inevitable Jurisdiction: Why unregulated modalities will soon draw regulatory oversight and how operators can prepare proactively.
• Pre-Build Compliance: Why conducting early site and plumbing scans prevents catastrophic, retroactive compliance costs.
• The Water Rights Crisis: How municipal water allocations, snowpack shortages, and local competition threaten expanding bathhouse footprints.
• Immersive Risk Audits: Aligning public marketing representations with client waivers and health disclosures to safeguard against liability.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Thinking about launching a health product, dietary supplement, or digital health solution in the Australian market? You might want to hit pause before assuming your U.S. or European regulatory strategy will translate. In this episode of the KLF Deep Dive, host Daran Carney connects with Isabelle Petour, Principal of Launchpad Regulatory, a boutique regulatory affairs firm based in Sydney. Together, they pull back the curtain on Australia's Therapeutic Goods Administration (TGA) and explore the fascinating, often surprising realities of navigating compliance down under.

Isabelle explains how the TGA’s uniquely strict definition of a "therapeutic good" instantly converts everyday Western cosmetics and food supplements into heavily regulated medicines. She dives into the strict form-factor rules—like why a simple liquid syrup can be labeled a food, but pressing that exact same liquid into a solid tablet immediately mandates a pharmaceutical drug listing. The conversation also uncovers how a lean agency of only a few hundred people achieves world-class oversight through global reliance programs like the PIC/S GMP guides and the five-nation Access Consortium. Whether you're exploring traditional Ayurvedic medicines, managing corporate firewalls between sales and medical affairs, or bracing for the TGA's ruthless "two-week window" compliance audits, this episode is your ultimate survival guide for the Australian healthcare market.

What You'll Learn in This Episode:

• The Food-Drug Interface: How the TGA applies the definition of therapeutic claims to capture and regulate performance-enhancing products and supplements.
• The Solid Oral Dosage Trap: Why the TGA automatically classifies tablets and capsules as therapeutic goods based on domestic choking risks and kitchen safety metrics.
• Global Reliance Networks: How the TGA leverages the Access Consortium (Australia, Canada, UK, Singapore, Switzerland) to split the labor of drug evaluations and fast-track global approvals.
• The Two-Week Audit Threat: Why sponsors of traditional and listed medicines must keep their scientific evidence ready on-hand, and the reality of random compliance sampling.
• Medical Affairs Governance: The rigid operational firewalls required by the Medicines Australia Code of Conduct to separate commercial sales from clinical discussions.

Support the show

www.kulkarnilawfirm.com